# A pilot study to determine whether increasing oxygen flow rate or oxygen percentage through a fixed performance mask relieves breathlessness in patients with cystic fibrosis

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
29/09/2006	Stopped	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
29/09/2006	Stopped	Results
Last Edited	Condition category	Individual participant data
06/10/2011	Nutritional, Metabolic, Endocrine	<ul><li>Record updated in last year</li></ul>

# Plain English summary of protocol

Not provided at time of registration

# **Contact information**

# Type(s)

Scientific

#### Contact name

Dr Andrew M Jones

#### Contact details

The Manchester Adult Cystic Fibrosis Centre South Manchester University Hospitals NHS Trust Wythenshawe Hospital Southmoor Road Manchester United Kingdom M23 9LT +44 0161 291 2154 andrew.jones@uhsm.nhs.uk

# Additional identifiers

## Protocol serial number

N0226167746

# Study information

#### Scientific Title

## Study objectives

To compare whether changing oxygen flow or oxygen percentage through a fixed performance mask relieves breathlessness in patients with cystic fibrosis.

## Ethics approval required

Old ethics approval format

# Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

# Study type(s)

**Treatment** 

## Health condition(s) or problem(s) studied

Nutritional, Metabolic, Endocrine: Cystic fibrosis

#### **Interventions**

Cohort of stable CF Patients. Patients will perform a maximal bicycle ergometric exercise test on room air (under supervision of a specialist CF physiotherapist and doctor) to determine work rate & associated peak respiratory flow rate. VAS is assessed each minute to specifically determine degree of breathlessness. Following the exercise test VAS is assessed in recovery.

Patients are rested and randomly assigned one of three exercise tests over two days. These exercise tests use either an increasing oxygen concentration mask (flow rate remains the same). Relief of breathlessness will be determined by VAS scoring.

Added Seyember 2008: trial stopped due to lack of resources.

## Intervention Type

Other

#### Phase

**Not Specified** 

#### Primary outcome(s)

Increasing oxygen flow rate is beneficial to breathless patients

# Key secondary outcome(s))

Not provided at time of registration

#### Completion date

30/12/2007

# Reason abandoned (if study stopped)

Lack of resources

# **Eligibility**

# Key inclusion criteria

- 1. Cystic fibrosis patients aged over 16
- 2. Clinically stable
- 3. Able to give informed consent

# Participant type(s)

**Patient** 

# Healthy volunteers allowed

No

## Age group

Adult

#### Sex

**Not Specified** 

# Key exclusion criteria

Patients having respiratory exacerbation

#### Date of first enrolment

01/07/2005

#### Date of final enrolment

30/12/2007

# Locations

## Countries of recruitment

**United Kingdom** 

England

# Study participating centre

The Manchester Adult Cystic Fibrosis Centre

Manchester United Kingdom M23 9LT

# Sponsor information

# Organisation

Record Provided by the NHSTCT Register - 2006 Update - Department of Health

# Funder(s)

# Funder type

Government

#### **Funder Name**

South Manchester University Hospitals NHS Trust (UK), NHS R&D Support Funding

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration